

Thursday, October 22, 8:00–9:30 a.m. MT

Opening Plenary

**Opening Plenary: ASN President's Address, State-of-the-Art Lecture,
Featured High-Impact Clinical Trials**

Bluebird Ballroom

*Note: Full abstracts will be posted on the ASN website on the day of presentation, and on the JASN website on November 10.
Abstracts in this session will have corresponding poster presentations on the same day in the Exhibit Hall.*

- 9:05 AM **TH-OR109 The ORIGIN 3 Trial: Atacicept in IgA Nephropathy** – Jonathan Barratt, Robert M. Brenner, Sean Barbour, Kirk N. Campbell, Tom Doan, Necmi Eren, Jürgen Floege, Marshall W. Fordyce, Vivekanand Jha, Zeeshan Khawaja, Beom Seok Kim, Adrian Liew, Bart D. Maes, Atanu Pal, Roberto Pecoits-Filho, Richard K. Phoon, Dana V. Rizk, Hitoshi Suzuki, Vladimir Tesar, Hernan Trimarchi, Xuelian Wei, Lixi Yu, Hong Zhang, Richard A. Lafayette
Corresponding Poster ID: TH-PO1257
- 9:12 AM **TH-OR110 Sibeprenlimab in IgA Nephropathy: 24 Months of Data from the Phase 3 VISIONARY Trial** – Dana V. Rizk, Jonathan Barratt, Yusuke Suzuki, Hong Zhang, Muh Geot Wong, Adrian Liew, Richard A. Lafayette, Vladimir Tesar, Hernan Trimarchi, Kevin Carroll, Ian Roberts, Vivekanand Jha, Maria A. Smuclir Quevedo, Seung Hyeok Han, Rosnawati Yahya, Chee Kay Cheung, Raja Ramachandran, Michael Walsh, Bobby Chacko, Manuel Praga, J. B. Chen, Jose H. Suassuna, Jing Xia, Lokesh N. Shah, Vlado Perkovic
Corresponding Poster ID: TH-PO1258
- 9:19 AM **TH-OR111 Telitacicept for IgA Nephropathy: Final Two-Year Results of the Phase 3 TELIGAN Trial** – Jicheng Lv, Lijun Liu, Sydney Tang, Wenxiang Wang, Heather N. Reich, Lin Li, Weihong Mao, Yifan Zhang, Jianmin Fang, Vlado Perkovic, Hong Zhang, TELIGAN Investigators
Corresponding Poster ID: TH-PO1256